阿来替尼治疗前后ALK突变状态:两项前瞻性试验汇总分析
该探索性分析汇总两项单臂II期研究(NP28673和NP28761),评估阿来替尼在克唑替尼耐药后ALK阳性NSCLC患者中的疗效。基线时48/187例(25.7%)检出34种ALK突变,无ALK单核苷酸变异者中位PFS为10.2个月,有突变者为5.6个月;阿来替尼进展后49例中26例(53%)检出16种ALK突变,其中31%为已知阿来替尼耐药突变。
要点
- 基线ALK突变者阿来替尼疗效较差,中位PFS 5.6个月 vs 10.2个月。
- 克唑替尼耐药后ALK突变患者中50%对阿来替尼应答。
- 阿来替尼进展后53%血浆样本检出ALK突变,31%为耐药突变。
核心结论
- 阿来替尼对ALK重排及多种克唑替尼耐药ALK突变具有临床活性。
- 血浆cfDNA或可作为无创监测耐药突变的替代方法。
研究设计与样本
- 探索性分析汇总两项单臂II期研究NP28673和NP28761。
- 纳入克唑替尼进展后的局部晚期/转移性ALK阳性NSCLC成人患者。
- 对187例克唑替尼后/阿来替尼前血浆cfDNA及49例阿来替尼进展后样本进行ALK突变分析。
主要发现
- 基线时48/187例(25.7%)检出34种不同ALK突变。
- 无ALK单核苷酸变异者(n=138)中位PFS为10.2个月(95%CI: 8.1-14.3),有突变者(n=48)为5.6个月(95%CI: 4.5-10.9)。
- 32例克唑替尼耐药ALK突变患者中16例(50%)对阿来替尼达部分缓解。
- 阿来替尼进展后49例中26例(53%)检出16种ALK突变,15/49(31%)为已知耐药突变I1171T/N/S、G1202R和V1180L。
临床怎么用
- 克唑替尼耐药后可通过血浆cfDNA检测ALK突变,辅助预测阿来替尼疗效。
- 阿来替尼进展后可行cfDNA监测耐药突变(如G1202R、I1171T/N/S、V1180L)。
局限性
- 探索性分析,样本量有限(基线187例,进展后49例)。
- 汇总两项单臂II期研究,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The effectiveness of ALK receptor tyrosine kinase (ALK) inhibitors can be limited by the development of ALK resistance mutations. This exploratory analysis assessed the efficacy of alectinib in patients with NSCLC and ALK point mutations using pooled data from two single-arm phase II studies. METHODS: Studies NP28673 and NP28761 enrolled adults with locally advanced/metastatic ALK-positive NSCLC who had progressed on crizotinib. ALK mutation analysis was conducted on cell-free DNA from 187 patients post-crizotinib/pre-alectinib, and from 49 of these patients who subsequently progressed on alectinib. RESULTS: Baseline characteristics were generally balanced across patient subgroups. At baseline, 34 distinct ALK mutations were identified in 48 of 187 patients (25.7%). Median investigator-assessed progression-free survival was longer in patients without ALK single-nucleotide variants (n = 138) versus those with (n = 48): 10.2 months (95% confidence interval [CI]: 8.1-14.3) versus 5.6 months (95% CI: 4.5-10.9), respectively. Sixteen of 32 patients (50%) with ALK resistance mutations to crizotinib achieved an investigator-assessed response to alectinib (all partial responses); most of these ALK mutations were known to be sensitive to alectinib. Analysis of plasma samples obtained post-progression on alectinib revealed that 26 of 49 (53%) samples harbored 16 distinct ALK mutations, with known alectinib-resistance mutations, I1171 T/N/S, G1202R, and V1180L, observed in 15 of 49 (31%) tumors. CONCLUSIONS: Alectinib appears clinically active against ALK rearrangements and mutations, as well as several ALK variants that can cause resistance to crizotinib. The use of cell-free DNA in plasma samples may be an alternative noninvasive method for monitoring resistance mutations during therapy.
引用
- Noé J, Lovejoy A, Ou SI, et al. ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. J Thorac Oncol. 2019. PMID: 31712133. doi:10.1016/j.jtho.2019.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。